Lilly Adds Two More Humalog Authorized Generics As Insurance Deductibles Reset
Executive Summary
With rebate reform efforts stalled, insulin manufacturer broadens efforts to lower prices through authorized generics, but PBMs may still like the big rebates they can get on the original brands.
You may also be interested in...
Did Lilly Overcome US Price Pressures In Last Quarter? Investors Await Answer
With business heavily dependent on sales revenue from Medicare Part D and other US government programs, Lilly will be expected to narrow the gap between US prescription and sales growth.
Insulin List Prices Would Be Lowered To 2006 Levels Under House Bill
Rebates would be prohibited and insurance coverage required without restrictions for insulin products with steep price roll-backs under bill from Reps. Diana DeGette, D-CO, and Tom Reed, R-NY.
Pharma's Big Defeat: US Rebate Proposal Hits The End Of The Road
White House will not move forward with a rebate proposal the drug industry supported as a way to lower patient drug spending.